PD-L1 expression was found to predict better outcomes with Opdivo and Yervoy in patients with ccRCC, while high KIM-1 levels ...
A multinational collaboration co-led by the Garvan Institute of Medical Research has uncovered a potential explanation for why some cancer patients receiving a type of immunotherapy called checkpoint ...
Tiragolumab is a novel immune checkpoint inhibitor that binds to TIGIT, a protein receptor on immune cells, which suppresses ...
GlobalData on MSN3d
Roche’s tiragolumab flops in another Phase III lung cancer trialTiragolumab missed the chance to prove a survival benefit in SKYSCRAPER-01 adding to previous trial failures for the ...
The addition of tiragolumab to Tecentriq in patients with advanced PD-L1-high NSCLC failed to improve overall survival in a Phase III trial.
HotCopper.com on MSN11d
Radiopharm extends radioimmunotherapy trial to 5 more cancer typesRadiopharm Theranostics Ltd (ASX:RAD) has received approval from the Australian Ethics Committee to expand its trial to ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback